Brusch J (2007) Surgical Treatment of Native Valve and Prosthetic Valve Infective Endocarditis Infective Endocarditis: Management in the Era of Intravascular Devices, 10.3109/9781420019834.015, ...

gstt.nhs.uk Infective endocarditis (ie, the infection of a native or prosthetic heart valve, the endocardium or implanted cardiac device1) is a clinical chameleon whose epidemiology and natural ...

Antimicrobial prophylaxis for prevention of HACEK bacterial endocarditis before invasive dental procedures should be reserved for selected high-risk patients with prosthetic heart valves, previous ...

Regarding the treatment of endocarditis, intravenous antibiotics are necessary for most patients for the time span of 4–6 weeks. Therefore, patients with infective endocarditis (IE) spend a long time ...

Background Native aortic and mitral valve infective endocarditis (AVE and MVE, respectively) are usually grouped together as left-sided native valve infective endocarditis (LNVE), while the ...

INTRODUCTION. Infective Endocarditis (IE) is a rare infectious condition of the endocardial surface of the heart. Despite current advances in its diagnosis and treatment modalities, IE continues to ...

Pediatr Infect Dis J. 2008;27(7):647-648. From the beginning, the scientific basis for recommendations for endocarditis prophylaxis was not well established. The evidence supporting prophylaxis ...

Multimodality imaging methods detect infection sources in a known case of cardiac device or prosthetic valve patients with high suspicion for infective endocarditis. Following recent guidelines and ...

Rapid identification and treatment of the causative organism is key in the successful treatment of bacterial infection. This can be difficult in conditions such as infective endocarditis when the ...

Bacterial prophylaxis, typically a fluoroquinolone, was used in 7/63 (11.1%) patients. Bacterial infections were observed in 49/63 (77.8%) patients, including 28 patients with more than 1 infection ...

Background Melody valved stents (Medtronic Inc, Minneapolis, Minnesota, USA) have become a very competitive therapeutic option for pulmonary valve replacement in patients with congenital heart disease ...